Increased sodium channel use-dependent inhibition by a new potent analogue of tocainide greatly enhances in vivo antimyotonic activity

Although the sodium channel blocker, mexiletine, is the first choice drug in myotonia, some myotonic patients remain unsatisfied due to contraindications, lack of tolerability, or incomplete response. More therapeutic options are thus needed for myotonic patients, which require clinical trials based...

詳細記述

保存先:
書誌詳細
出版年:Neuropharmacology
主要な著者: De Bellis, Michela, Carbonara, Roberta, Roussel, Julien, Farinato, Alessandro, Massari, Ada, Pierno, Sabata, Muraglia, Marilena, Corbo, Filomena, Franchini, Carlo, Carratù, Maria Rosaria, De Luca, Annamaria, Conte Camerino, Diana, Desaphy, Jean-François
フォーマット: Artigo
言語:Inglês
出版事項: Pergamon Press 2017
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5154332/
https://ncbi.nlm.nih.gov/pubmed/27743929
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.neuropharm.2016.10.013
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料